CD274 and nasopharyngeal carcinoma: Camrelizumab, a common drug for immunotherapy of nasopharyngeal carcinoma, is a humanized monoclonal antibody and effectively blocks the binding of PD-1/PD-L1, which plays a key role in tumor immune escape.